Master the Science of Natural Anti-Infectives with Aridis Pharmaceuticals (ARDS)
June 7, 2021
David Moadel
With a world-class intellectual property portfolio, Aridis is well-positioned to shift the paradigm in infectious disease treatment
The human immune system is a wonder of nature. Time and again, researchers have affirmed that our bodies can be remarkably effective in fighting even the deadliest of infections.
In virtually all outbreaks of infectious diseases, subsets of disease-free patients exist. Aridis Pharmaceuticals (ARDS) specializes in mining the immune responses of these infection survivors for their rare, protective monoclonal antibodies.
Aridis’ innovative approach to antibody discovery and development is designed to overcome the deficiencies associated with current therapies, such as drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives.
It’s an approach that’s poised to advance the science while potentially saving lives as human-derived, natural anti-infectives could become a vital weapon in combating the growing antibiotic resistance crisis.
A Closer Look at ARDS Stock
It’s predictable and investable: ARDS stock is sitting at the bottom of a well-defined range. $6 is the magic number as ARDS is known to bounce off of that level.
Again and again, ARDS stock has headed towards $8 for a quick 33% gain – it’s like picking money up off of the sidewalk.
After $8, the next target would be $11.50 as ARDS stock vaulted for that level three different times in 2019. Isn’t it funny, how the market literally tells you which levels to look out for?
The lowest I’ve ever seen ARDS stock go was $4.20, and that happened just briefly in late 2019 before the stock took off like a rocket ship.
If you see ARDS anywhere near that price, it’s time to back up the truck and start loading up with both hands.
Mining the Human Immune Response
Again, Aridis Pharmaceuticals prefers to leverage the human body’s own powerful responses to infectious diseases.
The company’s proprietary monoclonal antibody discovery platforms recover and immortalize the antibody-producing cells from infection survivors, turning them into therapeutic antibody producing factories.
Amazingly, these technologies allow for the discovery and manufacturing of monoclonal antibodies approximately one year faster than any other antibody discovery technologies currently available.
As a result, Aridis is able to generate an unrivaled product portfolio of novel anti-infective treatments:
AR-301 (Salvecin), a fully human monoclonal antibody that targets Staphylococcus aureus – in Phase 3 clinical trial
AR-101 (AerumabTM), a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11, which accounts for around 22% of all P. aeruginosa hospital-acquired infections worldwide – successfully completed Phase 2a clinical testing in hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) patients
AR-501 (Panaecin), a novel anti-infective for chronic lung infection associated with cystic fibrosis – currently being evaluated in a Phase 1/2a clinical study
AR-712, a monoclonal antibody cocktail being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate Covid-19 – in pre-clinical phase
AR-701, a monoclonal antibody cocktail designed to block the binding and propagation of infection by SARS-CoV-2 of human lung cells – pre-clinical
AR-401, a monoclonal antibody discovery program to treat infections caused by the Gram-negative bacterium Acinetobacter baumannii – pre-clinical
Critical Updates
As you can see, Aridis has a broad portfolio of infection-fighting treatments. The company also has two partnered products: AR-105 (Aerucin) to treat Pseudomonas aeruginosa, and AR-201, which is directed against the F-protein of the respiratory syncytial virus.
Moreover, Aridis Pharmaceuticals is progressing quickly in 2021, as evidenced by a number of vital program updates.
First, it was revealed that AR-712 targets not only the original SARS-CoV2 virus, but also its newly emerging variants, including the currently prevalent E484K strain associated with the South Africa, Brazil, and Japan variants, as well as the California strain, which harbors the L452R mutation.
Additionally, AR-501 is being developed in collaboration with the CF Foundation and has been granted Orphan Drug Designation (ODD), Fast Track and Qualified Infectious Disease Product (QIDP) designations by the FDA. In addition, the European Medicines Agency (EMA) granted ODD to AR-501.
Plus, it was recently reported that Aridis had total cash and cash equivalents of $10.5 million as of March 31, 2021 – a clear indication that the company is well-capitalized to pursue its breakthrough research.
The Final Word
Interestingly, Aridis Pharmaceuticals’ intellectual property portfolio is diversified, yet at the same time highly targeted as the company aggressively advances the healing potential of monoclonal antibodies.
The updates keep on coming as Aridis’ shareholders stay in the trade and await the next development in breakthrough science – and another breakout moment for ARDS stock.
ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.
